ClinicalTrials.gg
RecruitingNCT07358377Updated Aug 11, 2026

A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer

A Phase 1 interventional study of HRS-6209 Capsules and fulvestrant injection in Breast Cancer, sponsored by Atridia Pty Ltd.. Recruiting at 6 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Planned enrollment
77th of 94
15 · median 71
Started
2026
with 2 others
Phase 1
6 of 95
1 open now
Primary completion
2027-04
later than 11 of 22 live
Registered
94th of 95
by date

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 77th largest by planned enrollment of the 94 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 11 of the 22 other live ones, and was the 94th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive/HER2-Negative solid tumor.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial.
  2. Adequate bone marrow and other vital organ functions
  3. Adequate liver function tests
  4. HR-positive or -negative solid tumor patients

Exclusion criteria

Exclusion Criteria

  1. Plan to receive any other anti-tumor therapy during the study.
  2. Active .
  3. Have poorly controlled or severe cardiovascular disease, including (1) congestive heart failure.
  4. Previous use of fulvestrant
  5. endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding.
  6. With uncontrollable chronic systemic complications (such as severe chronic lung, liver, kidney, or heart disease).
  7. With acute or active tuberculosis infection requiring medication.
  8. Pregnant or lactating women, or females planning to become pregnant During the study.
  9. Known history of clinically significant liver disease, untreated active hepatitis (, defined as hepatitis B virus surface antigen [HBsAg] or hepatitis B core antibody [HBcAb] positive
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    HRS-6209 Capsules and fulvestrant injection

    Drug: HRS-6209 Capsules and fulvestrant injection

Interventions

  • DrugHRS-6209 Capsules and fulvestrant injection

    Drug pages: HRS-6209 · Fulvestrant

    HRS-6209, 100mg BID for 4 weeks, and single dose of fulvestrant injection

06

What researchers measure

Primary outcomes

  1. Safety by reporting incidence and severity of Adverse events (graded as per CTCAE V5.0) of adverse events (AEs) and serious adverse events (SAEs),

    To safety and tolerability of HRS-6209 in combination with fulvestrant in patients with advanced unresectable or metastatic breast cancer

    Time frame: Screening up to study completion,, an average of 1 year.

Secondary outcomes

  1. Concentration

    Plasma concentrations of HRS-6209 during multiple dosing, directly observed from data.

    Time frame: From administration to Cycle2 , up to 4 months.

  2. Cmax,ss

    Css, max are steady-state maximum concentrations of HRS-6209 during multiple dosing, and are directly observed from data.

    Time frame: From administration to Cycle2, up to 4 months.

  3. Cmin,ss

    Css, min are the steady-state trough concentrations of HRS-6209 during multiple dosing, and are directly observed from data.

    Time frame: From administration to Cycle2, up to 4 months.

  4. Objective Response Rate (ORR)

    ORR refers to the proportion of subjects with a complete response (CR) or partial response (PR) based on all soft tissue assessments recorded from the date of first drug administration to either the date of radiographic disease progression (including bone progression and soft tissue progression), death from any cause, or the initiation of a new antitumor therapy, whichever occurs first. For subjects with CR or PR at the first evaluation, the efficacy should be confirmed 4 weeks later or at the next tumor imaging evaluation. The numerator includes subjects with a confirmed CR/PR at least 4 weeks after the initial assessment. The denominator consists of subjects with measurable target lesions at baseline.

    Time frame: Screening up to study completion, an average of 2 years.

  5. Best of Response (DoR)

    BOR refers to the best response of tumor evaluation, including CR, PR, stable disease (SD), progressive disease (PD), and not evaluable for response (NE).

    Time frame: Screening up to study completion, an average of 2 years.

  6. Disease Control Rate (DCR)

    DCR refers to the time from the first occurrence of CR or PR to PD or death from any cause, whichever occurs first, in subjects with objective response. DCR will be recorded from baseline visit until the end of the study.

    Time frame: Screening up to study completion, an average of 2 years.

  7. rPFS (radiographic progression-free survival

    rPFS refers to the time from the first dose of investigational drug to the first radiographic PD or death from any cause (whichever occurs first) as assessed by the investigator. rPFS will be recorded from baseline visit until the end of the study.

    Time frame: Screening up to study completion, an average of 2 years.

07

Study locations

6 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Apr 2027, 10 months after the start.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 10 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2025
First posted
Jan 22, 2026
StartActual
May 15, 2026
Primary completionEst.
Apr 10, 2027
CompletionEst.
Nov 10, 2027
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07358377
Lead sponsor
Atridia Pty Ltd.
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
May 15, 2026
Primary completion
Apr 10, 2027 (estimated)
Completion
Nov 10, 2027 (estimated)
Last update
Aug 11, 2026

Study contacts

Kathy You
Contact
kathyyou@atridia.com
+61 02 9299 0433
Ravi Patel
Contact
ravi.patel@atridia.com
+61 452 363 506

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HRS-6209 · Fulvestrant

Start the discussion